Zebra Biologics

Zebra Biologics, Inc. is a biotechnology company based in Concord, Massachusetts, established in 2013. The company specializes in the discovery and development of biosuperior antibody therapeutics and complex drug targets to address clinical needs across a variety of disease areas, including diabetes, obesity, cancer, and neurological diseases. Zebra Biologics employs a drug development process that incorporates cellular function-based screening to identify and select fully human therapeutic biologics, such as antibodies, peptides, and proteins derived from DNA-encoded combinatorial libraries. Through its innovative approach, the company aims to advance medical treatments and improve patient outcomes.